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Background: In the absence of long-term, placebo-controlled studies of cholinesterase inhibitors 
in Alzheimer’s disease (AD), analysis of the results of open-label trials becomes crucial. This 
study aimed to explore the three-year effects of galantamine treatment, as well as subgroups of 
response and adherence to treatment.
Methods: Two hundred and eighty patients with a clinical diagnosis of AD were included in 
the prospective, open-label, multicenter Swedish Alzheimer Treatment Study, and received 
galantamine treatment. Efficacy measures included cognitive tests, ie, the Mini-Mental 
State Examination (MMSE) and Alzheimer’s Disease Assessment Scale Cognitive Subscale 
  (ADAS-cog), functional rating (Instrumental Activities of Daily Living Scale [IADL]), and 
global rating. Assessments were carried out before treatment and every six months for a period 
of three years. K-means cluster analysis was used to identify response subgroups.
Results: After three years of treatment, the mean change from baseline was 2.6 points in 
MMSE and 5.6 points in ADAS-cog scores. Globally, half of the patients improved or remained 
unchanged for two years. Cluster analysis identified two response clusters. Cluster 1 included 
patients with low ability in ADAS-cog and IADL scores at baseline. Even though the patients 
in cluster 1 were older and less educated, they responded better at six months compared with 
patients in cluster 2. Cluster 2 included patients with better ADAS-cog and IADL scores at 
baseline. Patients in cluster 2 had a higher frequency of the APOE ε4 allele, a slower pretreatment 
progression rate, and remained in the study longer than those in cluster 1. Three-year completers 
(n = 129, 46%) received higher doses of galantamine compared with dropouts.
Conclusion: AD patients who received long-term galantamine treatment were cognitively 
and globally stabilized. Subgroup response analysis identified a better short-term response in 
older patients with lower cognitive and functional abilities at baseline, a faster pretreatment 
progression rate, and a lower incidence of the APOE ε4 allele. The galantamine dose was higher 
in the population of completers.
Keywords: Alzheimer’s disease, long-term treatment, routine setting, cholinesterase inhibitor, 
galantamine, k-means cluster analysis, completion rates
Introduction
Alzheimer’s disease (AD) is the major cause of dementia, and underlies more than 60% 
of dementia cases.1 The incidence and prevalence of AD increase with age.2 Reports 
of increasing life expectancy in developed countries3 indicate that AD will be one of 
the biggest health care challenges in the future. Without treatment, AD is characterized 
by a progressive and irreversible decline in cognitive and practical abilities, leading 
to major difficulties after only a few years of disease duration.4
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In the 1990s, cholinesterase inhibitors (ChEIs) became 
the first drugs used to treat the symptoms of AD. ChEIs, 
which work by counteracting cholinergic deficits, and 
memantine, which inhibits glutamate overexpression, con-
tinue to be the drugs available for the treatment of AD.5 
The second-generation ChEIs include donepezil, rivastig-
mine, and galantamine. Galantamine, which is a competitive 
and rapidly reversible inhibitor of acetylcholinesterase and an 
allosteric modulator of nicotine receptors,6 gained approval in 
Sweden in 2000. Multiple double-blind, placebo-controlled 
clinical trials showed the beneficial effects of galantamine 
treatment on the cognitive and behavioral symptoms in AD 
patients for up to six months.7–9 Because ethical constraints 
prohibit the use of long-term, placebo-controlled studies of 
ChEIs in AD, the analysis of results from open-label, long-
term trials is important.
The response to ChEI varies within the AD population. 
Multiple factors have been outlined that enhance response 
to ChEI treatment in AD;10 however, there are no standard 
guidelines that define response to treatment. To overcome this 
issue, data-driven techniques, such as cluster analysis, could 
be used to investigate natural subgroups of AD populations 
in treatment studies.11 Low completion rates are another dif-
ficulty of long-term studies of AD patients, both with or with-
out treatment. Three-year completion rates range between 
4% and 39%,12–19 making it difficult to comprehend fully the 
long-term outcomes of treatment in AD. The investigation 
of treatment dropout and the search for methods aimed at 
enhancing completion rates and adherence to treatment are 
warranted in the field of AD research.
The Swedish Alzheimer Treatment Study was designed 
to evaluate the long-term effects of ChEI treatment in 
a routine clinical setting. Data obtained from patients 
treated with donepezil and rivastigmine were reported 
previously.20,21 The clinical outcome of and adherence to 
long-term galantamine treatment in a routine setting remain 
to be investigated.
In this report, we investigated the first 280 patients who 
received galantamine in the Swedish Alzheimer Treat-
ment Study program; these individuals were recruited 
until the end of 2005 and had the opportunity to participate 
for three years. The aims of this report are to describe the 
cognitive   (Mini-Mental State Examination [MMSE] and 
Alzheimer’s Disease Assessment Scale Cognitive Subscale 
[ADAS-cog]), functional (Instrumental Activities of Daily 
Living Scale [IADL]), and global outcomes of treatment, to 
identify treatment subgroups, and to investigate the rates of 
dropout and adherence to treatment.
Materials and methods
Subjects
Two hundred and eighty patients were recruited prospectively 
from 10 centers. The study data were collected by participat-
ing physicians at memory clinics across Sweden. The workup 
at baseline included medical history, informant-based infor-
mation, physical and neurological examination, extended 
cognitive testing, laboratory tests, and computed tomography 
or magnetic resonance imaging of the brain. In some centers, 
patients were investigated additionally using cerebrospinal 
fluid taps, APOE genotyping, measurements of regional 
cerebral blood flow (SPECT), electroencephalography, 
and neuropsychological testing; however, these were not 
criteria for inclusion. Patients fulfilled the clinical criteria 
of dementia, as defined by the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV),22 
and of probable or possible AD, according to the criteria 
of the National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association.23
The inclusion criteria were wide, and included AD patients 
aged older than 40 years, living at home at the time of diag-
nosis, having a caregiver, assessable via MMSE at baseline, 
and able to give their informed consent to participate in the 
study. Patients who did not fulfill the diagnostic criteria for 
AD and those already receiving active treatment with another 
ChEI or with contraindications to galantamine treatment were 
excluded from the study. The decision to start the patient on 
ChEI was made by the treating physician, in accordance with 
the standards used in routine clinical practice.
Medication other than antidementia drugs was allowed dur-
ing the study. Concomitant medications and their doses were 
recorded. If other dementia treatments (ie, memantine or study 
drugs) were added, patients left the study at that point.
All participating centers were trained in Good Clinical 
Practice, in diagnostics, and in the uniform use of the rat-
ing scales applied in this study. The data from the different 
centers were collected prospectively and the results were 
sent continuously to the Memory Research Unit in Malmö 
for monitoring and data handling. The study was approved by 
the ethics committee of the University of Lund. All patients 
and their closest relative/caregiver provided written informed 
consent to participate in the study, which was carried out in 
accordance with the Declaration of Helsinki.
Study design and outcome measures
Cognitive assessment was performed using the MMSE24 
and ADAS-cog (0–70).25 MMSE scores range from 0 to 30, 
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with a higher score indicating better function. Scores on the 
ADAS-cog version range from 0 to 70, with a higher score 
indicating lower function. ADAS-cog responses of patients 
at the different time intervals were investigated using the 
following cutoffs of change: “improved”, 4 or more points 
of improvement; “unchanged”, 3 to −3 points; and “worse”, 
4 or more points of deterioration.
Functional status was measured using the IADL scale,26 
which ranges from 8 to 31 points, with a higher value indicating 
more impaired function. The eight items on the IADL scale 
were telephone use, shopping, food preparation, housekeeping, 
laundry, transportation, medication, and finances. If an item 
was not applicable to the individual, its score was 0. Disease 
level at baseline was assessed using a seven-point scale (from 
“1 = normal” to “7 = very severe”).27 The Clinician’s Interview-
Based Impression of Change (CIBIC) rating28,29 was used as a 
global measure of “change from baseline”. The CIBIC uses a 
seven-point scale (from “1 = very much improved” to “7 = very 
much worse”), with a score of 4 indicating no change from 
baseline. No guidelines or descriptors were provided to define 
the individual ratings. Global rating was meant to measure the 
overall improvement, regardless of patient score on cognitive 
tests. Patients could be regarded as being globally better but 
still score less well on the cognitive tests. The distinction 
between minimally improved or much improved was left to 
the clinical judgment of the individual rater.
Baseline was defined as the assessment prior to the first 
dose of treatment. All patients assessed at baseline and 
treated with at least one dose of galantamine were included 
in the outcome analysis (observed cases). The assessments at 
baseline were performed before and close to the start of ChEI 
treatment. Patients were assessed for all outcome measures at 
baseline and every six months after the baseline assessment 
for a period of three years. In addition, MMSE and global 
rating were performed at the two-month visit.
Comparative analysis
The Stern equation was used to calculate the annual change 
in ADAS-cog score if the patients had not been treated.30 This 
equation is based on the ADAS-cog (0–70) of AD patients with 
a baseline ADAS-cog score in the range of 5–69 points.
The Stern equation is as follows:
Predicted ADAS-cog score at a time T  
  =   −6.039689 + 1.329485 xi − 0.005392 x2
i + (0.031974  
+ 0.036652 xi − 0.000473634 x2
i) T
where T is time from baseline and xi is baseline ADAS-cog 
score for an individual. The ADAS-cog value predicted using 
the Stern equation was calculated for each individual at each 
interval of the study. The mean change in ADAS-cog score 
from baseline was obtained based on these calculations. 
These scores were used as mathematical controls.
The annual decrease in MMSE score in untreated AD 
patients was estimated at 2–4 points per year, and the annual 
increase in ADAS-cog was estimated at 4–9 points per year, 
based on historical reports of annualized decline.30–33
Subgroup analysis
A cluster analysis was applied to investigate the possibility of 
identifying natural subgroups of clinically sensible patients 
(short-term response). Patient baseline values of IADL and 
ADAS-cog and their six-month rate of change were used as 
variables in the analysis. The analysis included only patients 
with complete data at six months.
The subgroups identified were described and compared. 
Differences in age, gender, duration of illness, number of 
years of education, APOE genotype (presence or absence of 
the APOE ε4 allele), number and type of medications at base-
line, galantamine dose, occurrence of dropout, MMSE level 
at baseline, and pretreatment progression rate in MMSE were 
investigated. Pretreatment progression rate was calculated 
using the following formula: 30-baseline MMSE/estimated 
duration of symptoms in years, as described previously.34
Treatment
After inclusion and baseline assessments, patients received 
galantamine treatment according to the approved product 
labeling, as in routine clinical practice. Patients were initially 
prescribed tablets, but when the extended-release capsules 
became available, patients switched to this formulation. 
All patients were started on a dose of 8 mg/day, which was 
increased to 16 mg/day after four weeks of treatment, aiming 
at a further dose increase to 24 mg/day. In some cases, the 
dose was reduced because of the presence of side effects. 
All decisions regarding dosage were left to the individual 
clinician, as in routine clinical practice, and all dosage adjust-
ments were recorded throughout the study. The patients paid 
for their medication in accordance with the standards of the 
Swedish health care system.
Dropout
Each center recorded the dates of dropout. The reasons 
for dropout were investigated and included admission 
to a nursing home, switch to another ChEI, death, with-
drawal of informed consent, reconsideration of the diag-
nosis, presence of side effects, compliance problems, 
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poor effect/  deterioration, somatic disease unrelated to 
  galantamine treatment, addon of memantine, entering 
another treatment study, and other reasons.
Predictors of dropout were investigated and included 
age, gender, duration of illness, number of years of educa-
tion, APOE genotype (presence or absence of the APOE 4 
allele), number of medications at baseline, type of medication 
at baseline, galantamine dose, and baseline MMSE, ADAS-
cog, and IADL scores.
Statistical analysis
The SPSS program, version 17.0 (SPSS Inc, Chicago, IL) 
was used to perform the statistical analyses. The level of 
significance was set at P , 0.05 if not otherwise specified. 
Nonparametric methods were used to avoid the possibility 
of skewed distributions. The Mann–Whitney U test was 
applied if two independent groups were compared. The χ2 
test was used to analyze nominal scale variables, eg, gender 
and APOE genotype.
The Wilcoxon signed-rank test was used to investigate 
differences in scores from the baseline to each assessment 
point. A logistic regression analysis using dropout (no/yes) as 
the dependent variable was applied to investigate predictors 
of discontinuation and their odds ratios.
A hierarchical cluster analysis using Ward’s method 
with squared Euclidean distance was applied to determine 
the adequate number of clusters. Agglomeration coefficients 
and dendrogram analysis displayed a two-cluster solution as 
the most optimal. Subsequently, a k-means cluster analysis 
with two clusters was applied using the baseline values of 
IADL, ADAS-cog, the six-month IADL scale, and ADAS-
cog change from baseline as independent variables in the 
analysis.
Results
Subjects
The baseline characteristics of the 280 patients are displayed 
in Table 1. The mean age was 73.1 ± 8.2 years, and 62% of 
the patients were female. The median level of education was 
9.8 ± 3.8 years. The mean duration of disease was 3.0 ± 1.7 
years. At baseline, the mean MMSE score was 23.2 ± 4.1 
and the ADAS-cog score was 16.8 ± 8.7. The mean baseline 
IADL score was 12.8 ± 5.2.
At baseline, 85% of the patients had concomitant medi-
cation (Table 1). The number of medications per person 
was 3.0 ± 2.7. The six groups of medication used by more 
than 10% of the study population are displayed in Table 1. 
The largest groups of medication were to treat vascular risk 
Table 1 Baseline characteristics and medication
Mean ± SD
Patients (n) 280
Males/females % 38/62
Living status (%)
Living alone 32
Living with family 68
Age at onset, years (range) 70.1 ± 8.5 (43–87)
Age at baseline, years (range) 73.1 ± 8.2 (47–88)
illness duration at baseline, years 3.0 ± 1.7
Years of education (range) 9.8 ± 3.8 (7–20)
APOE ε4 allele, carrier/noncarrier, n (%) 29/71 (274)
MMSE 23.2 ± 4.1 (280)
ADAS-cog (0–70), mean (n) 16.8 ± 8.7 (277)
iADL (n) 12.8 ± 5.2 (263)
PSMS (range) 7.0 ± 2.0
FAST (range) 3.4 ± 1.3
Preprogression rate, MMSE decline/year 3.2 ± 3.1
Medicationa n (%)
Any 236 (85)
Antihypertensives/cardiac therapy 105 (38)
Vitamins (folic acid, cobalamin) 89 (32)
Acetylsalicylic acid 81 (29)
Antidepressants 76 (27)
Lipid-lowering agents 50 (18)
Anxiolytics 35 (13)
Note: aAll baseline medications taken by more than 10% of the study population 
(n = 278), two patients did not provide baseline medication data. 
Abbreviations: ADAS-cog, the Alzheimer’s Disease Assessment Scale-cognitive 
subscale; iADL, instrumental Activities of Daily Living; SATS, Swedish Alzheimer 
Treatment Study; MMSE, Mini-Mental State Examination; SD, standard deviation; 
FAST, Functional Assessment Staging of Alzheimer’s Disease; PSMS, Physical Self-
Maintenance Scale.
  factors and included antihypertensive or cardiac therapy 
(38%), vitamins (B12 and/or folic acid, 32%), acetylsalicylic 
acid (29%), and lipid-lowering agents (18%). Medications 
for psychiatric symptoms included antidepressants (27%) 
and anxiolytics (13%). In addition 5%–9% of the patients 
used antidiabetic agents, analgesics (other than acetyl-
salicylic acid and nonsteroidal anti-inflammatory drugs), 
thyroid hormone therapy, and antacids and acid reducers. 
Less than 5% of the patients used antipsychotics, estrogen, 
nonsteroidal anti-inflammatory drugs, gingko/vitamin E, or 
asthma medication.
Study outcomes
Mini-Mental State Examination
The mean MMSE scores and the mean changes from base-
line at the different visits are shown in Table 2. The mean 
MMSE score was 23.2 ± 4.1 at baseline and 21.7 ± 5.7 after 
36 months. The MMSE score was significantly better at two 
months (P , 0.001) and at six months (P = 0.006) compared 
with baseline, and was stable at 12 months (P = 0.616) 
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Figure  1  Mean  changes  in  score  from  baseline  (95%  confidence  interval)  in 
galantamine-treated patients. The shaded area is an estimated annual deterioration 
of 2–4 points per year as described in historical cohorts of untreated patients.
Abbreviation: MMSE, Mini-Mental State Examination.
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Figure 2 Mean changes in ADAS-cog score from the baseline (95% Ci) in galantamine-
treated patients. They were significantly better compared with the predicted change 
for untreated patients, calculated using the Stern equation (95% Ci), from 12 months 
and onwards. 
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; 
CI, confidence interval
  compared with baseline (Wilcoxon signed-rank test). 
  However, it   deteriorated after this time point. The MMSE 
changes from baseline over time are depicted in Figure 1 and 
Table 2. The total mean decline in MMSE score from baseline 
after three years of treatment was 2.6 ± 4.1. This three-year 
result was in accordance with the results described previ-
ously for one year (2–4-point change) in historical cohorts 
of untreated patients.32,35,36
Alzheimer’s Disease Assessment  
Scale-cognitive subscale
The mean ADAS-cog scores and their mean changes from 
baseline are presented in Table 2. The mean ADAS-cog 
(0–70) score was 16.8 ± 8.7 at baseline and 19.4 ± 12.6 after 
36 months of treatment. The ADAS-cog (0–70) changes 
from baseline over time are described in Figure 2. The total 
change in ADAS-cog score after three years of treatment 
was 5.6 ± 10.1 points above the baseline values. This was 
significantly better than the expected change in ADAS-cog 
of 12.6 ± 6.2, as calculated using the Stern equation (Table 2 
and Figure 2). Furthermore, it was better than the expected 
annual decline of 4–8 points recorded in untreated histori-
cal cohorts.30,37 The ADAS-cog scores at six months were 
not different from those recorded at the baseline (stable, 
P = 0.248, Wilcoxon signed-rank test), but deteriorated 
after that. ADAS-cog responses at all time intervals (which 
were defined as “improved”, 4 or more points improvement; 
“unchanged”, 3 to -3 points of variation; and “worse”, 4 points 
or more of deterioration) are displayed in Figure 3B.
instrumental Activities of Daily Living
Mean IADL scores and their changes from the baseline are 
presented in Table 2. The IADL scores deteriorated compared 
with baseline at all time points (Wilcoxon signed-rank test).
Clinician’s interview Based impression of Change
The mean CIBIC scores are displayed in Table 2. In sum-
mary, three groups were defined based on the CIBIC ratings. 
A CIBIC score of 1–3 was considered as “improved”, a 
CIBIC score of 4 was considered “unchanged”, and a CIBIC 
score of 5–7 as “worse”. At two months, 93% of the patients 
remaining in the study were “improved or unchanged” at 
months 6, 12, 24, and 36, 81%, 69%, 50% and 41% of 
the patients were “improved or unchanged”, respectively 
(Figure 3A).
Subgroup analysis
A dendrogram hierarchical cluster analysis (Ward’s method) 
suggested a two-cluster solution. Cluster 1 was composed of 
76 patients with a baseline IADL level of 16.9 ± 5.3 points, 
an ADAS-cog score of 25.9 ± 6.5 points, and a six-month 
ADAS-cog improvement from baseline of 2.0 ± 5.5 points. 
Cluster 2 was composed of 147 patients with a baseline 
IADL level of 10.3 ± 3.4 points, an ADAS-cog score of 
11.4 ± 4.0 points, and a six-month ADAS-cog deteriora-
tion from baseline of 0.77 ± 4.2 points (Table 3). Patients 
in cluster 1 were significantly older at baseline (P = 0.002) 
and at onset (P = 0.003) had a worse MMSE level at baseline 
(P , 0.001), exhibited a faster pretreatment progression 
rate (P , 0.001), and were more prone to dropout from the 
study (P , 0.001) than the patients in cluster 2. Patients 
in cluster 2 had a higher frequency of the APOE ε4 allele 
(P = 0.027) and a higher level of education (P = 0.007) than 
the patients in cluster 1. The patients in the two clusters did 
not differ regarding gender, dose of galantamine, number 
of medications at baseline, or disease duration (Table 3). 
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Figure 3 Global rating (CIBIC) was at all intervals compared with baseline. “Improved” was defined as a CIBIC score of 1–3, “unchanged” was defined as a CIBIC score of 4, 
and “worse” was defined as a CIBIC of 5–7. ADAS-cog responses at all time intervals. “Improved” was defined as 4 or more points improvement, “unchanged” was defined 
as 3 to −3 points of variation, and “worse” was defined as 4 points or more of deterioration.
Abbreviations: CiBiC, Clinician’s interview Based impression of Change; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale.
Patients in cluster 2 received significantly more lipid-
lowering medication than patients in cluster 1 (P = 0.019); 
otherwise, the type of medication did not differ between the 
two clusters (Table 3).
Patients not included in the cluster analyses because 
of missing data (n = 59) were treated with a lower dose of 
galantamine (14.1 ± 4.1 mg) compared with the patients 
who provided data for the cluster analysis (16.0 ± 3.1 mg). 
However, they did not differ from the patients included 
in the cluster analyses regarding any of the other aspects 
mentioned above.
Treatment
The mean dose of galantamine was 15.6 ± 3.4 mg, and the 
mean doses of galantamine administered at the different time 
points are displayed in Table 2.
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Dropout
Completion rates are displayed in Table 2. The reasons for 
dropout are described in Table 4. The three most common 
causes of dropout were not associated with stopping galan-
tamine treatment. Twenty-five percent of the patients left 
the study when memantine was added to the galantamine 
  treatment. Another 15% of the patients left the study 
because they were recruited to other studies, eg, vaccina-
tion   programs. In addition, 13% left the study at the time 
they moved to a nursing home but continued galantamine 
treatment.   However, moving to a nursing home was not an 
end point of the study. Twenty-three patients continued in 
the Swedish Alzheimer Treatment Study after nursing home 
placement and contributed data to the study.
The baseline characteristics of the completers and non-
completers of the present study were compared. Patients 
who left the study during the three-year interval had a sig-
nificantly higher baseline ADAS-cog score (P , 0.001), a 
lower MMSE score (P , 0.001), and a higher IADL score 
(P , 0.001) compared with patients who remained in the 
study, thus indicating a more severe disease level. Moreover, 
the mean galantamine dose administered to noncompleters 
was lower (16.5 ± 4.6 mg) compared with that administered 
to completers (18.0 ± 3.1 mg; P , 0.004). The dropouts 
did not differ in number of medications at baseline, age 
at onset, age at baseline, duration of illness, education in 
years, gender, or APOE genotype compared with patients 
who completed the three years of the study. No differences 
in medication profiles at baseline were observed regarding 
use of any of the medication groups between the dropouts 
and completers. Similar results were obtained using a logis-
tic regression model. A higher MMSE score at baseline 
(P , 0.001; odds ratio, 0.857) reduced the risk of dropout by 
14.3% per MMSE point increase. Moreover, a higher dose of 
galantamine (P , 0.001; odds ratio, 0.81) reduced the risk 
of discontinuation by 19% for every milligram increase in 
galantamine dose. However, age, IADL at baseline, APOE 
genotype, years of education, and number of medications 
did not influence dropout.
Discussion
AD patients treated with galantamine in a routine clini-
cal setting exhibited cognitive stabilization for up to one 
year after the onset of treatment. After three years of 
treatment, the mean MMSE change from baseline was 
2.6 points. Subgroup response was assessed using cluster 
analyses, and two stable clusters were identified. Patients 
with higher age, lower cognitive and functional ability 
at baseline, faster pretreatment progression rate, and 
lower frequency of the APOE ε4 allele exhibited a better 
short-term response to treatment, but dropped out earlier. 
Moreover, a high adherence to treatment was observed 
compared with that reported by earlier studies, and the 
three-year completers received higher galantamine doses 
than the noncompleters.
The routine clinical setting, which renders our results 
relevant also for the “ordinary” AD patient, was one of the 
advantages of the present study. This is especially important 
because the highly selected cohorts used in placebo-controlled 
Table 3 Characteristics of clusters
Characteristics Cluster 1  
(n = 76)
Cluster 2  
(n = 147)
P value 
(Mann- 
Whitney)
ADAS-cog (70), mean ± SD 25.9 ± 6.5 11.4 ± 4.0 ,0.001
iADL, mean ± SD 16.9 ± 5.3 10.3 ± 3.4 ,0.001
ADAS-cog change at  
6 months, mean ± SD
2.0 ± 5.5 −0.8 ± 4.2 ,0.001
iADL change 6 months −1.5 ± 3.4 −1.0 ± 2.7 0.233
Age at onset, mean ± SD 72.3 ± 8.6 68.8 ± 8.5 0.003
Age at baseline, mean ± SD 75.4 ± 8.2 71.8 ± 8.1 0.002
Duration of disease  
at baseline
2.9 ± 1.8 3.0 ± 1.8 0.635
Female gender, % 64 60 0.491a
MMSE at baseline,  
mean ± SD
19.4 ± 3.1 25.3 ± 2.8 ,0.001
Dropouts during study (%) 71 39 ,0.001a
APOE ε4 allele carrier (%) 62 76 0.027a
Galantamine dose, mg,  
mean ± SD
16.2 ± 3.0 15.7 ± 3.4 0.311
Education, years 8.8 ± 3.1 10.3 ± 4.0 0.007
Medications (n) 2.7 ± 2.6 3.1 ± 2.8 0.305
Preprogression rate,  
MMSE decline/year
5.2 ± 3.5 2.3 ± 2.3 0.001
Notes: For clarity, clinical improvements in both scales is tabulated as a positive 
change from baseline as have all the other measures. aChi-square. 
Abbreviations: ADAS-cog, the Alzheimer’s Disease Assessment Scale-cognitive 
subscale; iADL, instrumental Activities of Daily Living; SATS, Swedish Alzheimer 
Treatment Study; MMSE, Mini-Mental State Examination; SD, standard deviation.
Table 4 Study dropouts
Direct reason for dropout, total (n) 151
Adding memantine 37
Taking part in another study 23
Admission to nursing home 19
Side effects 14
Deterioration 11
Compliance problems 10
Death 10
Withdrawal of informed consent 10
Other reason 13
Missing 4
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trials may not be representative of patients in a real clinical 
setting.38 Moreover, even though we used a clinical routine 
setting, the data were collected prospectively and the evalu-
ation was structured and standardized.
One of the limitations of long-term AD studies is the 
absence of a control group, which is not possible to obtain 
for ethical reasons. Because long-term, placebo-controlled 
studies in AD are limited in time to a duration of six months, 
the analysis of long-term outcome is limited to open-label 
studies. Because AD is a disease with a duration of decades, 
these open follow-up investigations are important.
The present study showed that mean MMSE levels in 
AD patients were improved over six months and were stable 
for up to one year after the onset of treatment. Stabilization 
over one year has been described previously in cohorts of 
galantamine-treated patients.39 The expected annual decline 
in MMSE score described previously was 2–4 points in 
nontreated historical cohorts32,35,36 and 2.2 points in placebo-
treated patients.33 In the present study, the mean change in 
MMSE score from the baseline was 2.6 points, after not one 
but three years of treatment.
Moreover, the three-year deterioration in ADAS-cog score 
was 5.6 points compared with the one-year deterioration of 
8 points described in older untreated AD cohorts30,31 and the 
18-month deterioration of 6.7 points observed in a more recent 
study of a cohort with milder AD.40 The consistency between 
the outcomes obtained using two different scales strengthens 
these results. However, comparison of the outcomes of our 
study with those observed in previous placebo-controlled 
cohorts or earlier long-term studies must be performed with 
caution. Differences in cohorts, level of disease, and study 
design can influence the outcome. In an earlier analysis of 
Swedish Alzheimer Treatment Study data stemming from a 
donepezil-treated cohort, our group demonstrated a decline 
in MMSE score of 3.8 points after three years of treatment.21 
Because that cohort was, on average, older and more cogni-
tively impaired at treatment onset compared with the patients 
presented in the current study, the comparison of these results 
remains difficult, but will be obtained by our group in the 
future using statistical methods such as mixed models.
In the study presented here, 69% of the patients were 
globally assessed as “improved or unchanged” at one year, 
50% were “improved or unchanged” at two years, and 41% 
were “improved or unchanged” at three years. This result was 
better than that observed in an earlier three-year follow-up 
study of donepezil-treated patients (49%, 35%, and 30%, 
respectively),21 as well as that observed in nontreated cohorts 
(34%, 13%, 14%, respectively).17
The response to ChEI treatment varies among the AD 
population. AD is a heterogeneous condition, and it is 
likely that the efficacy of various therapies differs among 
subgroups. This can depend not only on the medication 
used, but also on factors influencing disease progression 
(“how fast”) or disease severity (“how far”). Severity of 
disease and fast progression rate predict a positive short-
term response to ChEI treatment in AD.41,42 However, the 
existence of malignant forms of AD with a fast progression 
rate and a lack of short-term response to ChEI treatment has 
also been reported.43 The definition of treatment response 
therefore remains difficult. There are no standard guidelines 
to describe response to treatment, and different definitions of 
response have been used previously.10 To overcome these dif-
ficulties in response definition, data-driven techniques, such 
as cluster analysis, may be better suited to the investigation 
of natural subgroups in AD treatment studies. Rockwood 
et al applied a cluster analysis to define outcome groups 
among a three-year completer population of AD patients.44 
In the study presented here, we included not only the com-
pleter population, but all patients who provided at least six 
months of data. A stable two-cluster model was obtained, 
with different responses and characteristics. In our model, 
the response defined by the cluster analysis showed that 
patients exhibiting a better response at six months (cluster 1, 
n = 76) had lower baseline ADAS-cog and IADL scores and 
a faster pretreatment progression rate, which was in line 
with earlier observations using other response definitions. 
The calculated estimation of pretreatment progression rate34 
yielded the same predictive response (faster pretreatment 
progression/better short-term response) as that described in 
earlier cohorts for which pretreatment progression rate was 
measured, rather than being calculated.42
Analysis of the differences between dropouts and com-
pleters of the present study showed that the three-year com-
pleters had less advanced disease at baseline and received 
higher doses of galantamine than the noncompleters. Low 
doses of ChEIs have been associated with early discontinua-
tion45 and some studies showed that higher ChEI doses enhance 
short-term response.46 These results stress the importance of 
using adequate ChEI doses in AD treatment to enhance adher-
ence and response to treatment. Patients in cluster 2 dropped 
out to a lesser extent than patients in cluster 1. However, these 
two clusters did not differ in galantamine dose, but patients in 
cluster 2 were treated with lipid-lowering medication at base-
line to a greater extent than patients in cluster 1. A protective 
effect of this medication cannot be ruled out, but this remains 
to be explored further using larger cohorts.
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In our cohort, 27% of patients were medicated with 
antidepressants at baseline, ie, before inclusion in the study. 
This figure is not high in naturalistic cohorts, because sev-
eral studies show that AD patients have a large comorbidity 
with depression, ranging from 20% to 30%. Among large 
European naturalistic AD cohorts, a 24% depression rate 
was described in one study47 and in another study anti-
depressants were prescribed to 34% of the patients.48 We 
know that the patients receiving antidepressants at baseline 
did not drop out to a greater extent than the ones without 
this treatment.
High dropout rates are a problem in all long-term AD 
studies. Appendix 1 provides an overview of dropouts in vari-
ous long-term studies to highlight this issue.   Three-year com-
pletion rates of 4%–39% are reported. Thus, the   three-year 
completion rate of 46% obtained in the current study is high 
compared with that of other long-term AD   studies. In the 
present study, the two major reasons for dropout were addi-
tion of memantine or recruitment of patients to other treat-
ment studies. As new treatment options emerged, patients 
were free to leave the present study to try other options. We 
do not know at this point whether these patients would have 
contributed to a different outcome if they had remained in the 
present study for the three-year period. We know that they 
were younger and better educated (data not shown), but did 
not differ in MMSE or ADAS-cog scores at baseline from 
the other dropout groups (data not shown). However, the 
possibility that patient deterioration was one of the reasons 
for adding memantine cannot be ruled out.
A recent observational health database study revealed 
that only 54% of patients receiving galantamine continued 
to do so for one year,49 which was longer than that observed 
for the donepezil-treated and rivastigmine-treated patients 
included in the same survey. Enhancement of the completion 
rates in long-term AD studies will be crucial in future studies 
of protective treatments, because these must be performed 
on a long-term basis.
Conclusion
Long-term galantamine treatment in a routine clinical set-
ting resulted in stabilization of cognitive and global decline 
in AD patients. Moreover, after two years of treatment, half 
of the patients showed cognitive and global stabilization of 
their condition. We identified subgroups of patients with 
differential responses to treatment and dropout. The   Swedish 
Alzheimer Treatment Study protocol used in this clinical 
setting may have contributed to the high completion rates 
observed in this study.
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The Swedish Alzheimer Treatment Study 
Group steering committee
Lennart Minthon (principal investigator), Niels Andreasen, 
Sture Eriksson, Annacarin Björkman (study coordinators); 
Lennart Minthon, Åsa Wallin, Carina Wattmo, Annacarin 
Björkman, Cecilia Dahl, Clinical Memory Research Unit, 
Department of Clinical Sciences, Malmö, Lund University, 
Malmö; Stellan Båtsman, Anett Wunsch, Department of 
  Primary Care, Kalix; Maria Eriksdotter Jönhagen, Niels 
Andreasen, Christina Sjödin, Department of Neurotec, 
  Section Clinical Geriatrics, Karolinska Institutet, Alzheimer’s 
Disease Research Center, Karolinska University   Hospital, 
Completion rates in long-term studies of Alzheimer’s disease
MMSE (mean)  
baseline level
Baseline  
(n)
1-year 2-year 3-year 4-year 5-year
Randomized controlled trials
Mohs et al54 (don) 17.1 431 26%
Winblad et al33 (don) 19.4 286 67%
Courtney et al12 (AD2000, don)a 19 (median) 565 52% 20% 3.5%
Randomized controlled trials with open-label extensions
Rogers et al16 (don)b 27 (mean ADAS-cog) 133 75% 29% 22% 15% 3%
Doody et al50 (don)c (range 10–26) 763 75% 48%  7%d    
Grossberg et al51 (riv) 19.4 2010 74% 48%      
Pirtilla et al15 (gal) 19.4 1039   47% 30%e    
Small et al14 (riv) 19.3 1998 74% 52% 33% 15% 4%
Winblad et al13 (don) 19.4 286 67% 49% 39%    
Open studies from naturalistic settings
Minthon et al20 SATS (riv) 22.9 217 89% 66%
Wallin et al21 SATS (don) 22.0 435 82% 60% 38%
Lyle et al18 (don) 18.8 88 57% 43% 20% 12%
Raschetti et al52 (don, riv, gal) 18.2 5462 52%f
Wallin et al19 (tacrine) 20.5 50 66% 46% 30% 26% 16% (4%  
with MMSE)
Without treatment
Holmes and Lovestone17  
(no treatment)
17.0 151 66% 44% 32%
Head-to-head studies
Bullock et al53 (riv, don) 994 58%
Notes: aMultiple washout periods; b161 patients entered 12-week randomized controlled trial, 2 weeks washout, 133 entered open phase; c3-week or 6-week washout 
periods before open-label study started; d2.8 years; e64% of 12-month completers, continuous 24 mg galantamine treatment; fnine months.
Abbreviations: ADAS-cog, the Alzheimer’s Disease Assessment Scale-cognitive subscale; don, donezepil; riv, rivastigmine; gal, galantamine; SATS, Swedish Alzheimer 
Treatment Study; MMSE, Mini-Mental State Examination.
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Geriatric Clinic, Härnösands Hospital, Härnösand; Kristina 
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